Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527537 | 0.82 | NAMPT (0.53) | NR1I3MEN1KMT2ANAMPTDRD2 | |
| SCHEMBL4771671 | 0.80 | NR1I3 (0.47) | NR1I3DRD4NAMPTDRD2 | |
| SCHEMBL7673219 | 0.76 | NAMPT (0.53) | RBP4NAMPT | |
| SCHEMBL2930032 | 0.75 | HSD17B10 (0.43) | MEN1KMT2AHTT | |
| SCHEMBL7670250 | 0.73 | NAMPT (0.54) | NAMPT | |
| SCHEMBL8333919 | 0.73 | GPR119 (0.54) | MEN1KMT2ANAMPT | |
| SCHEMBL7667732 | 0.71 | NAMPT (0.48) | RBP4CYP2C19NAMPT | |
| SCHEMBL6321208 | 0.71 | BACE1 (0.48) | CHRM3KMT2ANAMPT | |
| SCHEMBL7667690 | 0.71 | NAMPT (0.52) | NAMPT | |
| SCHEMBL8908801 | 0.71 | MAPK1 (0.57) | MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | TERT 3325/4885SIGMAR1 4325/4885NR1I3 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.